Welcome to our dedicated page for Novocure SEC filings (Ticker: NVCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NovoCure Limited filings document the oncology device company's operating results, product and regulatory updates, and governance for its Tumor Treating Fields business. Recent Form 8-K reports include quarterly and annual financial results, FDA approval disclosure for Optune Pax, clinical-trial updates for pancreatic cancer, Medicare billing-status disclosure and executive compensatory arrangements.
Proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. The filing record also identifies NovoCure as a Jersey-incorporated registrant under the Nasdaq ticker NVCR and records formal disclosures tied to its commercial products, clinical programs and reimbursement matters.
Mukund Paravasthu filed a Form 144 reporting a proposed sale of 5,377 shares of common stock.
The filing lists prior sales in the past three months: 408 shares on 03/02/2026 and 1,555 shares on 02/27/2026. The securities are common stock intended for sale under Rule 144 on NASDAQ.
NVCR filed a Form 144 reporting a proposed sale of 5,607 restricted common shares through Morgan Stanley Smith Barney LLC dated 03/04/2026. The filing also lists recent dispositions: 7,232 shares sold on 03/02/2026 and 9,734 shares sold on 02/27/2026, each with associated dollar figures in the excerpt.
NovoCure Ltd Chief Medical and Innovation Officer Uri Weinberg reported a mix of share grants and mandated sales. On February 28, he acquired 12,992 ordinary shares at $0.00 per share from vesting of performance-based restricted stock units. Around these vestings, a total of 10,733 shares were sold in open-market transactions on February 27 and March 2 at weighted average prices of about $13.84 and $13.33 per share to cover tax withholding obligations under NovoCure’s equity plans, described as non-discretionary “sell to cover” trades. After these transactions, Weinberg directly owned 223,477 ordinary shares.
NovoCure Ltd’s Chief Human Resources Officer, Michal Nath Puri, reported an automatic sale of 1,441 Ordinary Shares. The shares were sold on February 27, 2026 in open-market trades at a weighted average price of about $13.66 per share, within a range of $13.45 to $13.97.
According to the filing, this was a mandatory “sell to cover” transaction to satisfy tax withholding obligations tied to the vesting of Restricted Stock Units, not a discretionary trade. After this sale, Puri directly held 162,322 Ordinary Shares of NovoCure.
NovoCure Ltd Chief Operating Officer Paravasthu Mukund reported mandated tax-related share sales. He sold a total of 1,963 ordinary shares in open-market transactions, including 1,555 shares on February 27, 2026 at a weighted average price of $13.6638 and 408 shares on March 2, 2026 at a weighted average price of $13.4930.
The filing notes these shares were sold to cover tax withholding obligations arising from vesting of Restricted Stock Units under NovoCure’s equity incentive plans, and the sales were required by a “sell to cover” arrangement rather than being discretionary trades. After these transactions, Mukund directly owns 76,343 ordinary shares.
NovoCure Ltd insider Nicolas Leupin, the company’s former Chief Medical Officer, reported an open-market sale of 1,029 ordinary shares on February 27, 2026 at a weighted average price of $13.6638 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units under NovoCure’s equity incentive plans, as required by the award agreement. After this tax-related, non-discretionary “sell to cover” transaction, Leupin continued to hold 104,079 ordinary shares directly.
NovoCure Ltd’s Chief Executive Officer Leonard Frank X reported a mix of share awards and sales. On February 28, 2026, performance-based restricted stock units vested into 18,621 ordinary shares at no cost to him. Around this vesting, he executed open-market sales totaling 16,966 ordinary shares on February 27 and March 2, 2026 at weighted average prices of about $13.66 and $13.49 per share. A footnote explains that these sales were mandated "sell to cover" transactions to satisfy tax withholding obligations under the company’s equity plans, rather than discretionary trades. Following these transactions, he directly holds 349,400 ordinary shares of NovoCure.
NovoCure Ltd’s former Chief Executive Officer Ashley Cordova reported a mix of equity award activity and related tax withholding. On February 28, 2026, Cordova acquired 23,818 Ordinary Shares at $0.00 per share from the vesting of performance-based restricted stock units.
On February 27 and March 2, 2026, Cordova disposed of Ordinary Shares in several tax-withholding dispositions tied to restricted stock unit vesting. These non-discretionary transactions withheld 11,541 shares at $13.75, and 2,410 and 7,228 shares at $13.67, to cover tax obligations as approved under Rules 16b-3(e) and 16b-3(d)(1).
NovoCure Ltd reported an insider equity award for its General Counsel, Ben Arye Barak. He acquired 17,755 ordinary shares on February 28, 2026 at a stated price of $0.00 per share, described as the vesting of performance-based restricted stock units.
Following this grant/vesting, Barak’s direct holdings increased to 192,328 ordinary shares. This transaction reflects stock-based compensation rather than an open-market purchase or sale.